Hamed SA. Topiramate induced peripheral neuropathy: A case report and review of literature. World J Clin Cases 2017; 5(12): 446-452 [PMID: 29291205 DOI: 10.12998/wjcc.v5.i12.446]
Corresponding Author of This Article
Dr. Sherifa Ahmed Hamed, MD, Professor, Consultant Neurologist, Department of Neurology and Psychiatry, Assiut University Hospital, Floor # 7, Room # 4, Assiut 71516, Egypt. sherifa.omran@med.au.edu.eg
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 16, 2017; 5(12): 446-452 Published online Dec 16, 2017. doi: 10.12998/wjcc.v5.i12.446
Topiramate induced peripheral neuropathy: A case report and review of literature
Sherifa Ahmed Hamed
Sherifa Ahmed Hamed, Department of Neurology and Psychiatry, Assiut University Hospital, Assiut 71516, Egypt
Author contributions: Hamed SA solely contributed to this paper.
Institutional review board statement: This case report was exempt from the Institutional Review Board standards at University of Assiut in Egypt.
Informed consent statement: The patient involved in this study gave her written informed consent authorizing use and disclosure of her protected health information.
Conflict-of-interest statement: The author declared no conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Sherifa Ahmed Hamed, MD, Professor, Consultant Neurologist, Department of Neurology and Psychiatry, Assiut University Hospital, Floor # 7, Room # 4, Assiut 71516, Egypt. sherifa.omran@med.au.edu.eg
Telephone: +20-88-2371820 Fax: +20-88-2333327
Received: June 9, 2017 Peer-review started: June 15, 2017 First decision: August 7, 2017 Revised: August 11, 2017 Accepted: September 3, 2017 Article in press: September 4, 2017 Published online: December 16, 2017
Core Tip
Core tip: Peripheral neuropathy is a rare adverse effect of short- or long-term use of antiepileptic drugs (phenytoin, phenobarbital, carbamazepine, valproate, gabapentin, levetiracetam and lacosamide). This is the first case report of topiramate induced peripheral neuropathy (TIPN). Manifestations of TIPN are distal paresthesia, areflexia, sensory deficits and reduced amplitudes and nerve conduction velocities of motor and sensory peripheral nerves of the lower extremities indicating demyelinating and axonal neuropathies. The risk is greater with long-term therapy. The mechanisms of TIPN may involve impairment of nerve function through blocking of sodium voltage channels, enhancement of gamma amino butyric acid inhibitory neurotransmission or others.
